Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Market watch: Top drugs and companies by sales in 2017Nature reviews. Drug discovery, 2018-04, Vol.17 (4), p.232-232 [Peer Reviewed Journal]COPYRIGHT 2018 Nature Publishing Group ;Copyright Nature Publishing Group Apr 2018 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2018.42 ;PMID: 29588516Full text available |
|
2 |
Material Type: Article
|
Antibiotic Resistance — Problems, Progress, and ProspectsThe New England journal of medicine, 2014-11, Vol.371 (19), p.1761-1763 [Peer Reviewed Journal]Copyright © 2014 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMp1408040 ;PMID: 25271470Full text available |
|
3 |
Material Type: Article
|
Contribution of NIH funding to new drug approvals 2010–2016Proceedings of the National Academy of Sciences - PNAS, 2018-03, Vol.115 (10), p.2329-2334 [Peer Reviewed Journal]Volumes 1–89 and 106–114, copyright as a collective work only; author(s) retains copyright to individual articles ;Copyright © 2018 the Author(s). Published by PNAS. ;Copyright National Academy of Sciences Mar 6, 2018 ;Copyright © 2018 the Author(s). Published by PNAS. 2018 ;ISSN: 0027-8424 ;EISSN: 1091-6490 ;DOI: 10.1073/pnas.1715368115 ;PMID: 29440428Full text available |
|
4 |
Material Type: Article
|
The $2.6 Billion Pill — Methodologic and Policy ConsiderationsThe New England journal of medicine, 2015-05, Vol.372 (20), p.1877-1879 [Peer Reviewed Journal]Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMp1500848 ;PMID: 25970049Full text available |
|
5 |
Material Type: Article
|
New uses for old drugsNature (London), 2007-08, Vol.448 (7154), p.645-646 [Peer Reviewed Journal]COPYRIGHT 2007 Nature Publishing Group ;COPYRIGHT 2007 Nature Publishing Group ;Copyright Nature Publishing Group Aug 9, 2007 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/448645a ;PMID: 17687303 ;CODEN: NATUASFull text available |
|
6 |
Material Type: Article
|
The antibiotic paradox: why companies can't afford to create life-saving drugsNature (London), 2020-08, Vol.584 (7821), p.338-341 [Peer Reviewed Journal]COPYRIGHT 2020 Nature Publishing Group ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/d41586-020-02418-x ;PMID: 32814891Full text available |
|
7 |
Material Type: Article
|
An urgent call to raise the bar in oncologyBritish journal of cancer, 2021-11, Vol.125 (11), p.1477-1485 [Peer Reviewed Journal]2021. The Author(s). ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-021-01495-7 ;PMID: 34400802Full text available |
|
8 |
Material Type: Article
|
Potential Life‐Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in CanadaThe oncologist (Dayton, Ohio), 2020-01, Vol.25 (1), p.e130-e137 [Peer Reviewed Journal]AlphaMed Press 2019 ;AlphaMed Press 2019. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2019-0314 ;PMID: 31506392Full text available |
|
9 |
Material Type: Article
|
Theranostic radiopharmaceuticals: established agents in current useBritish journal of radiology, 2018-11, Vol.91 (1091), p.20170969-20170969 [Peer Reviewed Journal]2018 The Authors. Published by the British Institute of Radiology 2018 The Authors ;ISSN: 0007-1285 ;EISSN: 1748-880X ;DOI: 10.1259/bjr.20170969 ;PMID: 29474096Full text available |
|
10 |
Material Type: Article
|
Economics of New Oncology Drug DevelopmentJournal of clinical oncology, 2007-01, Vol.25 (2), p.209-216 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2006.09.0803 ;PMID: 17210942Full text available |
|
11 |
Material Type: Article
|
Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price TagCirculation (New York, N.Y.), 2021-06, Vol.143 (25), p.2494-2496 [Peer Reviewed Journal]ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.121.055463 ;PMID: 34152800Full text available |
|
12 |
Material Type: Article
|
How drugs are developed and approved by the FDA: current process and future directionsThe American journal of gastroenterology, 2014-05, Vol.109 (5), p.620-623 [Peer Reviewed Journal]Copyright Nature Publishing Group May 2014 ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.1038/ajg.2013.407 ;PMID: 24796999Full text available |
|
13 |
Material Type: Article
|
Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory AgenciesThe New England journal of medicine, 2012-06, Vol.366 (24), p.2284-2293 [Peer Reviewed Journal]Copyright © 2012 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;Copyright © 2012 Massachusetts Medical Society. 2012 ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMsa1200223 ;PMID: 22591257 ;CODEN: NEJMAGFull text available |
|
14 |
Material Type: Article
|
FDA new drug approvals in Q3 2020Nature reviews. Drug discovery, 2020-11, Vol.19 (11), p.746-746 [Peer Reviewed Journal]COPYRIGHT 2020 Nature Publishing Group ;Nature 2020. ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/d41573-020-00182-1 ;PMID: 33046853Full text available |
|
15 |
Material Type: Article
|
Drug Safety Sciences and the Bottleneck in Drug DevelopmentClinical pharmacology and therapeutics, 2011-06, Vol.89 (6), p.788-790 [Peer Reviewed Journal]2011 American Society for Clinical Pharmacology and Therapeutics ;ISSN: 0009-9236 ;EISSN: 1532-6535 ;DOI: 10.1038/clpt.2011.63 ;PMID: 21593756Full text available |
|
16 |
Material Type: Article
|
Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of CardiologyEuropean heart journal, 2016-03, Vol.37 (9), p.747-754 [Peer Reviewed Journal]Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com. ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehv213 ;PMID: 26077039Full text available |
|
17 |
Material Type: Article
|
Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act CoveragePLoS medicine, 2017-01, Vol.14 (1), p.e1002190-e1002190 [Peer Reviewed Journal]COPYRIGHT 2017 Public Library of Science ;COPYRIGHT 2017 Public Library of Science ;2017 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Kesselheim AS, Treasure CL, Joffe S (2017) Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. PLoS Med 14(1): e1002190. doi:10.1371/journal.pmed.1002190 ;2017 Kesselheim et al 2017 Kesselheim et al ;2017 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Kesselheim AS, Treasure CL, Joffe S (2017) Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. PLoS Med 14(1): e1002190. doi:10.1371/journal.pmed.1002190 ;ISSN: 1549-1676 ;ISSN: 1549-1277 ;EISSN: 1549-1676 ;DOI: 10.1371/journal.pmed.1002190 ;PMID: 28045970Full text available |
|
18 |
Material Type: Article
|
Speed, Safety, and Industry Funding — From PDUFA I to PDUFA VIThe New England journal of medicine, 2017-12, Vol.377 (23), p.2278-2286 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMhle1710706 ;PMID: 29211663Full text available |
|
19 |
Material Type: Article
|
Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payersNature reviews. Drug discovery, 2010-04, Vol.9 (4), p.277-291 [Peer Reviewed Journal]COPYRIGHT 2010 Nature Publishing Group ;Copyright Nature Publishing Group Apr 2010 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd3079 ;PMID: 20186141Full text available |
|
20 |
Material Type: Article
|
The current challenges for vaccine developmentJournal of medical microbiology, 2012-07, Vol.61 (Pt 7), p.889 [Peer Reviewed Journal]EISSN: 1473-5644 ;DOI: 10.1099/jmm.0.039180-0 ;PMID: 22322337Full text available |